key: cord-0787284-244avw21
authors: Melhaoui, Imane; Oujidi, Younes; El Heddad, Inass Arhoun; Bensaid, Amine; Bkiyar, Houssam; Bentata, Yassamine; Housni, Brahim
title: Management of post cardiac transplantation immunosuppression and COVID-19: a case report
date: 2021-09-21
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.102875
sha: 6dd17b80305ca7653aaaec3922463cc43c8d82e5
doc_id: 787284
cord_uid: 244avw21

BACKGROUND: There is very limited experience in management of heart transplant (HT) recipients and their immunosuppressive drug therapies while confronted with a SARS-CoV-2 infection. CASE DETAILS: We report the case of a 60-year-old male, heart transplant recipient patient, admitted in our ICU for severe COVID-19. His immunosuppressors were discontinued. He presented an ARDS, a multiple organ failure and a refractory septic shock that eventually resulted in his death. DISCUSSION: Multiple studies reported a lower incidence of SARS-Cov-2 infection in HT recipients compared to the general population, probably due to their prior knowledge and use of protective and barrier measures; but when infected they tend to have poorer outcomes and higher fatality; on account of their pre-existing comorbidities and immunodeficiency. Therefore, the management of the immunosuppressive therapy raises a challenge, in the absence of trials. Physicians rely on experts’ recommendations, to maintain the immunosuppressors in case of mild COVID-19, lower to the bare minimum or even discontinue them in case of critical COVID-19 or systemic complications. CONCLUSION: COVID-19 infection is associated with poor outcomes and high mortality in HT recipients, and their immunosuppressive therapy management still raises questions and challenges in the absence of trial-validated data.

Multiple studies reported a lower incidence of SARS-Cov-2 infection in HT recipients compared to the general population, probably due to their prior knowledge and use of protective and barrier measures; but when infected they tend to have poorer outcomes and higher fatality; on account of their pre-existing comorbidities and immunodeficiency. Therefore, the management of the immunosuppressive therapy raises a challenge, in the absence of trials. Physicians rely on experts' recommendations, to maintain the immunosuppressors in case of mild COVID-19, lower to the bare minimum or even discontinue them in case of critical COVID-19 or systemic complications.

Conclusion: COVID-19 infection is associated with poor outcomes and high mortality in HT recipients, and their immunosuppressive therapy management still raises questions and challenges in the absence of trialvalidated data.

Since its emergence in December 2019, the Coronavirus disease (COVID-19) has caused a global pandemic and resulted in a substantial worldwide morbidity and mortality.

The resulting major health crisis has caused an unprecedented effect on various diseases and their management, especially in the transplantation field; and with relatively limited data and knowledge on SARS-CoV-2 effects on the body, many questions remain unanswered. Post-transplant patients are considered fragile and therefore more likely to be affected by the COVID-19; by not only their immunosuppression treatment, but also, their comorbidities and further contact with hospitals and Health workers.(1) The balance between a COVID-19 infection and its rapid progression under an immunosuppressor treatment and the immunodeficiency it causes and the possible rejection of the transplanted organ is the principal dilemma professionals are exposed to. (2) We report the case of a heart transplant patient infected with the SARS-CoV-2 treated for a COVID-19 pneumopathy at our intensive care unit.

This case report has been reported in line with the SCARE Criteria (10) .

This is a 60-year-old male patient, with hypertension and diabetes mellitus under treatment. He underwent heart transplantation on 2017 in Spain, and currently under immunosuppressors: Tacrolimus 1mg and Mycophenolate mofetil 0.5mg, twice daily.

He reported a recent trip to Spain two weeks before the symptoms for a checkup with his doctors, but had no contact with any known-SARS-CoV-2 infected individuals.

The patient had a history of fever, runny nose, sore throat and dry cough evolving for 8 days prior to his admission. His evolution worsened and he developed dyspnea and chest pain, motivating his visit to the emergency room.

Clinically, the patient was conscious, hemodynamically stable, with an oxygen saturation of 78% in ambient air; 96% under 15L oxygen with a high concentration mask. He also had a normal body temperature.

Biologically, he had a lymphocytopenia at 220 elements/m3, a normal troponin level of 17 ng/mL, with positive inflammation markers: C-reactive protein level at 106 mg/L, Ferritin level 679 mg/L; fibrinogen level at 8.7 mg/L, Lactic dehydrogenase (LDH) level at 370 mg/L. A SARS-CoV-2 reverse transcriptase PCR was performed and came back positive.

Arterial blood gas was performed and showed a hypoxemia with a PaO2 at 41mmHg.

He also benefitted from a thoracic CT-scan with an extent of pulmonary damage of 75%, and a cardiac evaluation with a normal transthoracic echocardiography.

A non-invasive ventilation based on High Flow Nasal Cannula (HFNC) was started at the 2end day of his admission; the immunosuppressors were discontinued and he was put under: Azithromycin, Vitamin C 2g/day, Zinc 45mg/day, Enoxaparin 0.6UI/12h, Dexamethasone 6mg/day; Aspirin 160mg/day and antibiotics: 3rd generation Cephalosporins 2g/day and quinolones (Ciprofloxacin 200mg/12h). He also received two doses of Tocilizumab (400mg with a 10day interval).

His antibiotics were changed to Piperacillin-Tazobactam 4g/8h, Amikacin 1,5g/day and Voriconazole 200mg/12h when nosocomial infection was confirmed by culture.

The patient unfortunately presented complications, such as acute respiratory distress syndrome in the 3erd day of admission, and was intubated and put under intensive mechanical ventilation. the progression of the disease was very fast for his case He presented a multi-organ failure (acute kidney injury and disseminated intravascular coagulation) and a refractory septic shock in 2end days after intubation, that resulted in his death at one week of his admission .

When confronted with this new COVID-19 pandemic, clinicians found themselves challenged while facing immunocompromised transplant recipients and their SARS-CoV-2 infection; and how their immunosuppressors intake's role in the systemic inflammatory response. (2) Two meta-analysis conducted in Germany by Rivinius et al. and However, when affected, heart transplant recipients are more likely to report a severe COVID-19 with higher ICU admission rate, increased mechanical ventilation need, and a higher mortality risk. (3) The effect of immunosuppressors therapy on the COVID-19 infection is nowadays still a matter of debate. In fact, in vitro data suggest that immunosuppressive therapy (such as Interferon and Cyclosporine) might result in the inhibition of viral replication by altering the T-cell response (3) (4) (5) and have therefore a protective mechanism; however long-term immunosuppression is known to increase infection-risk. (6) Concerning the management of immunosuppressive therapy in a heart transplant recipient infected with SARS-CoV-2, no evidence-based data is validated. Strategies are based upon expert opinions and transplant societies recommendations, and these guidelines are based upon the severity of the COVID-19 illness:

-If mild COVID-19 (no dyspnea or hypoxemia, oxygen saturation >94%); the immunosuppressors are maintained with a frequent monitoring for worsening symptoms.(7,8) -If the disease is moderate or severe, the patients must obviously be treated with in-hospital supportive care; many centers suggest keeping only the antiproliferative agents (such as Mycophenolate mofetil or Azathioprine) and to a bare minimum; with a monitoring of their lymphocyte count. (7) -If the disease becomes critical (complications such as respiratory failure requiring ventilation support or ECMO, circulatory collapse, acute kidney failure, cardiomyopathy…) all immunosuppressive drug therapy must be discontinued. (8) Corticosteroids such as (dexamethasone 6mg/d up to 10 days) can be instituted, to avoid adrenal insufficiency (7) and for being associated to survival improvement in patients under ventilation support. (9)

Heart transplant recipients are believed to be at a higher COVID-19 infection risk and associated with a higher ICU admission rate, more severe COVID-19, and higher mortality risk, due to their pre-existing comorbidities and their immunodeficiency status.

Regarding maintaining or discontinuing immunosuppressive drug therapy we can only depend on expert opinions, in the wait of future investigations and trial-validated data.

Strong efforts must be carried out to control the pandemic spread and avoid its poor outcomes especially in the absence of a cure. 

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

This is a case report that does not require a formal ethical committee approval.

Data were anonymously registered in our database. Access to data was approved by the head of the department.

Guarantor: Dr Imane Melhaoui and Dr Oujidi Younes.

We would like to thank the medical and nursing teams of Mohammed VI University Hospital for their significant involvement in the management of the patients included in our study.

The authors declare that they have no competing interests.

The authors declare that they have no funding.

None.

Not commissioned, externally peer reviewed. Demographic Details -Include de-identified demographic details of the patient (e.g. age, sex, ethnicity, occupation).

-Where possible, include other useful pertinent information (e.g. body mass index, hand dominance, income, level of education, marital status).

Presentation -Describe the patient's presenting complaint.

-Include a collateral account of the history if relevant.

-Describe the patient's mode of presentation (e.g. selfpresentation, ambulance or referred by family physician or other hospital clinicians).

Past Medical and Surgical History -Include any previous interventions and relevant outcomes.

Drug History and Allergies -Specify any acute, repeat, and discontinued medications.

-Include any allergies and/or adverse reactions.

Family History -Health information regarding first-degree relatives, specifying any inheritable conditions.

History -Indicate smoking, alcohol, and recreational drug use.

-Level of social independence, driving status, and type of accommodation.

-If appropriate, report on any other information gathered outside of the focused history. 3

-Bedside (e.g. urinalysis, electrocardiography, echocardiography).

-Laboratory (e.g. biochemistry, haematology, immunology, microbiology, histopathology).

-Imaging (e.g. ultrasound, X-ray, CT/MRI/PET).

-Invasive (e.g. endoscopy, biopsy).

Diagnostic Challenges -Where applicable, describe what was challenging about the diagnoses (e.g. access, financial, cultural).

Diagnostic Reasoning -Describe the differential diagnoses, why they were considered, and why they were excluded.

Prognostic Characteristics -Include where applicable (e.g. tumour staging).

3

Pre-Operative Patient Optimisation -Lifestyle (e.g. weight loss).

-Medical (e.g. medication review, treating any relevant pre-existing medical concerns).

-Procedural (e.g. nil by mouth, enema).

-Other (e.g. psychological support). -Where (e.g. home via video consultation, primary care, secondary care).

-How (e.g. telephone consultation, clinical examination, blood tests, imaging).

-Any specific long-term surveillance requirements (e.g.

imaging surveillance of endovascular aneurysm repair or clinical exam/ultrasound of regional lymph nodes for skin cancer).

-Any specific post-operative instructions (e.g. post-3 operative medications, targeted physiotherapy, psychological therapy).

Intervention Adherence and Compliance -Where relevant, detail how well the patient adhered to and tolerated the advice provided (e.g. avoiding heavy lifting for abdominal surgery, or tolerance of chemotherapy and pharmacological agents).

-Explain how adherence and tolerance were measured. -All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavien-Dindo Classification (e.g.

blood loss, length of operative time, wound complications, re-exploration or revision surgery).

-If relevant, was the complication reported to the relevant national agency or pharmaceutical company.

-Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not).

-Where applicable, the 30-day post-operative and longterm morbidity/mortality may need to be specified.

-State if there were no complications or adverse outcomes. -Disclose whether the case has been presented at a conference or regional meeting. 

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.

This is a case report that does not require a formal ethical committee approval. Data were anonymously registered in our database. Access to data was approved by the head of the department.

J o u r n a l P r e -p r o o f Consent Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".

Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.

Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

COVID-19 among heart transplant recipients in Germany: a multicenter survey

Massachusetts General Hospital and Harvard Medical School, Boston M. The Immunocompromised Transplant Recipient and SARS-CoV-2 Infection

Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: A descriptive survey report

A proposed strategy for management of immunosuppression in heart transplant patients with COVID-19

Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model

Covid-19 and Kidney Transplantation

Post-transplant immunosuppression and COVID-19: From a double whammy to a mixed blessing

Coronavirus disease 2019 (COVID-19): Outpatient evaluation and management in adults -UpToDate